Production of an anti-prostate-specific antigen single-chain antibody fragment from Pichia pastoris

被引:12
作者
Wang, YJ [1 ]
Wang, K [1 ]
Jette, DC [1 ]
Wishart, DS [1 ]
机构
[1] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada
基金
英国医学研究理事会; 加拿大自然科学与工程研究理事会;
关键词
single-chain Fv; prostate-specific antigen; Pichia pastoris;
D O I
10.1006/prep.2001.1521
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Prostate-specific antigen (PSA) is a widely used marker for screening and monitoring prostate cancer. Because PSA levels are normally quite low, an antibody-based assay must be used to detect PSA. However, not all PSA-specific antibodies bind equally well to PSA or to its different isoforms. Therefore, a better understanding of how PSA interacts with PSA-specific antibodies is of considerable clinical interest. B80.3 is a widely used murine monoclonal anti-PSA antibody (IgG), which has very high affinity for both free and anti-chymotrypsin complexed PSA. More importantly, its gene sequence is known-making it one of only two anti-PSA antibodies that has been fully cloned and sequenced. To better elucidate the interaction between PSA and B80.3, a single-chain antibody fragment, derived from the variable domain of B80.3 (scFvB80), was cloned into a pPIC9 vector and expressed in pichia pastoris. The secreted protein was purified using a three-step protocol beginning with a 50% ammonium sulfate precipitation step, followed by a T-gel thio-affinity step and concluding with a simple anion-exchange (DE52) filtration step. NMR studies indicate the protein is correctly folded while competitive enzyme-linked immunosorbant assays show that the purified scFvB80 has approximately 20% of the activity of the full-length B80.3 antibody. The protocol described here provides a quick and convenient route to prepare large quantities of very pure anti-PSA antibody fragments (15-20 mg/L culture medium) for detailed structural and biophysical characterization. (C) 2001 Academic Press.
引用
收藏
页码:419 / 425
页数:7
相关论文
共 38 条
[21]   High level secretion of single-chain antibody in Pichia expression system [J].
Luo, D ;
Mah, N ;
Krantz, M ;
Wishart, D ;
Jacobs, F ;
Martin, L .
BIOTECHNOLOGY TECHNIQUES, 1997, 11 (10) :759-761
[22]  
Luo Dong, 1995, Journal of Biochemistry (Tokyo), V118, P825
[23]   Three-dimensional structures of single-chain Fv-neuraminidase complexes [J].
Malby, RL ;
McCoy, AJ ;
Kortt, AA ;
Hudson, PJ ;
Colman, PM .
JOURNAL OF MOLECULAR BIOLOGY, 1998, 279 (04) :901-910
[24]  
MILENIC DE, 1991, CANCER RES, V51, P6363
[25]   Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma [J].
Nicholson, IC ;
Lenton, KA ;
Little, DJ ;
Decorso, T ;
Lee, FT ;
Scott, AM ;
Zola, H ;
Hohmann, AW .
MOLECULAR IMMUNOLOGY, 1997, 34 (16-17) :1157-1165
[26]  
Piironen T, 1998, PROTEIN SCI, V7, P259
[27]   HOW TO USE PROSTATE-SPECIFIC ANTIGEN [J].
PLOCH, NR ;
BRAWER, MK .
UROLOGY, 1994, 43 (02) :27-35
[28]   SINGLE-CHAIN FVS [J].
RAAG, R ;
WHITLOW, M .
FASEB JOURNAL, 1995, 9 (01) :73-80
[29]  
REITER Y, 1994, J BIOL CHEM, V269, P18327
[30]   STABILIZATION OF THE FV FRAGMENTS IN RECOMBINANT IMMUNOTOXINS BY DISULFIDE BONDS ENGINEERED INTO CONSERVED FRAMEWORK REGIONS [J].
REITER, Y ;
BRINKMANN, U ;
KREITMAN, RJ ;
JUNG, SH ;
LEE, B ;
PASTAN, I .
BIOCHEMISTRY, 1994, 33 (18) :5451-5459